Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Get Free Report) COO Eben Tessari sold 14,000 shares of Kiniksa Pharmaceuticals stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $19.57, for a total value of $273,980.00. Following the sale, the chief operating officer now directly owns 81,975 shares in the company, valued at approximately $1,604,250.75. This trade represents a 14.59 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.
Eben Tessari also recently made the following trade(s):
- On Monday, January 13th, Eben Tessari sold 14,000 shares of Kiniksa Pharmaceuticals stock. The stock was sold at an average price of $18.24, for a total value of $255,360.00.
Kiniksa Pharmaceuticals Stock Up 0.5 %
Kiniksa Pharmaceuticals stock traded up $0.09 during mid-day trading on Friday, hitting $19.74. The company's stock had a trading volume of 640,902 shares, compared to its average volume of 639,943. The stock has a market capitalization of $1.43 billion, a P/E ratio of -140.99 and a beta of 0.32. Kiniksa Pharmaceuticals, Ltd. has a twelve month low of $16.56 and a twelve month high of $28.15. The stock's fifty day moving average price is $19.82 and its two-hundred day moving average price is $22.84.
Hedge Funds Weigh In On Kiniksa Pharmaceuticals
Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. PDT Partners LLC grew its position in Kiniksa Pharmaceuticals by 74.3% during the 4th quarter. PDT Partners LLC now owns 64,917 shares of the company's stock worth $1,284,000 after purchasing an additional 27,675 shares in the last quarter. Northern Trust Corp grew its position in Kiniksa Pharmaceuticals by 11.1% during the 4th quarter. Northern Trust Corp now owns 283,599 shares of the company's stock worth $5,610,000 after purchasing an additional 28,393 shares in the last quarter. Oberweis Asset Management Inc. grew its position in Kiniksa Pharmaceuticals by 18.0% during the 4th quarter. Oberweis Asset Management Inc. now owns 237,200 shares of the company's stock worth $4,692,000 after purchasing an additional 36,200 shares in the last quarter. Voya Investment Management LLC grew its position in Kiniksa Pharmaceuticals by 16.8% during the 4th quarter. Voya Investment Management LLC now owns 19,988 shares of the company's stock worth $395,000 after purchasing an additional 2,870 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD grew its position in Kiniksa Pharmaceuticals by 23.6% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 15,111 shares of the company's stock worth $299,000 after purchasing an additional 2,881 shares in the last quarter. 53.95% of the stock is currently owned by hedge funds and other institutional investors.
Analysts Set New Price Targets
KNSA has been the topic of several recent analyst reports. Wedbush reissued an "outperform" rating and set a $34.00 target price on shares of Kiniksa Pharmaceuticals in a report on Monday, January 13th. Evercore ISI boosted their target price on Kiniksa Pharmaceuticals from $30.00 to $35.00 and gave the stock an "outperform" rating in a report on Wednesday, October 30th. Finally, JPMorgan Chase & Co. boosted their target price on Kiniksa Pharmaceuticals from $39.00 to $40.00 and gave the stock an "overweight" rating in a report on Tuesday, November 5th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Kiniksa Pharmaceuticals has a consensus rating of "Buy" and a consensus price target of $36.60.
Get Our Latest Stock Analysis on Kiniksa Pharmaceuticals
About Kiniksa Pharmaceuticals
(
Get Free Report)
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.
See Also
Before you consider Kiniksa Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kiniksa Pharmaceuticals wasn't on the list.
While Kiniksa Pharmaceuticals currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
